US sweet protein startup Oobli has raised $18M and partnered with global ingredients giant Ingredion to develop ...

"Anti-vaccine rhetoric is a threat to global health," said biomedical scientist Andrea C. Love, PhD, emphasizing how ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Flowers Foods Inc. stands “very well-prepared” amid a consumer migration away from traditional white and wheat loaf bread ...

Viewers of the Super Bowl may have seen an ad from one of the largest compounders in the United States, Hims & Hers, ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

When Trova Wine and Market shut its doors last month after nearly five years in business in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like ...